OBJECTIVE: Ghrelin is an orexigenic peptide implicated in body weight regulation, while cachexia is a multifactorial effect of non-small cell lung cancer (NSCLC) presented in patients with advanced disease. The aim of this study was to detect the role of ghrelin in cachexia and systemic inflammation of advanced NSCLC patients as well as its role as a diagnostic and prognostic tool. METHODS: Ghrelin serum levels were measured in 101 inoperable NSCLC patients before receiving any therapy (75 patients with weight loss and 26 without weight loss) and 60 healthy control volunteers. Epidemiological, anthropometrical and laboratory data were assessed for all participants (patients and healthy volunteers). RESULTS: NSCLC patients presented significantly higher ghrelin serum levels than healthy individuals, adjusted for sex, age and BMI (0.5+/-0.4 ng/ml vs. 0.4+/-0.3 ng/ml, P<0.001). NSCLC patients with weight loss presented significantly increased ghrelin serum levels (0.56+/-0.24 ng/ml vs. 0.52+/-0.44 ng/ml, P=0.017), compared to NSCLC patients without weight loss. CONCLUSIONS: Ghrelin serum levels are significantly increased in NSCLC patients, mainly in the subgroup of patients diagnosed with cachexia, indicating a possible implication in the pathogenesis of lung cancer. Further studies are needed to determine its potential role as predictive and prognostic marker.
OBJECTIVE:Ghrelin is an orexigenic peptide implicated in body weight regulation, while cachexia is a multifactorial effect of non-small cell lung cancer (NSCLC) presented in patients with advanced disease. The aim of this study was to detect the role of ghrelin in cachexia and systemic inflammation of advanced NSCLCpatients as well as its role as a diagnostic and prognostic tool. METHODS:Ghrelin serum levels were measured in 101 inoperable NSCLCpatients before receiving any therapy (75 patients with weight loss and 26 without weight loss) and 60 healthy control volunteers. Epidemiological, anthropometrical and laboratory data were assessed for all participants (patients and healthy volunteers). RESULTS:NSCLCpatients presented significantly higher ghrelin serum levels than healthy individuals, adjusted for sex, age and BMI (0.5+/-0.4 ng/ml vs. 0.4+/-0.3 ng/ml, P<0.001). NSCLCpatients with weight loss presented significantly increased ghrelin serum levels (0.56+/-0.24 ng/ml vs. 0.52+/-0.44 ng/ml, P=0.017), compared to NSCLCpatients without weight loss. CONCLUSIONS:Ghrelin serum levels are significantly increased in NSCLCpatients, mainly in the subgroup of patients diagnosed with cachexia, indicating a possible implication in the pathogenesis of lung cancer. Further studies are needed to determine its potential role as predictive and prognostic marker.
Authors: Timo D Müller; Diego Perez-Tilve; Jenny Tong; Paul T Pfluger; Matthias H Tschöp Journal: J Cachexia Sarcopenia Muscle Date: 2010-12-17 Impact factor: 12.910
Authors: Hyun Jung Kim; Han Jo Kim; Jina Yun; Kyoung Ha Kim; Se Hyung Kim; Sang-Cheol Lee; Sang Byung Bae; Chan Kyu Kim; Nam Su Lee; Kyu Taek Lee; Seong Kyu Park; Jong Ho Won; Hee Sook Park; Dae Sik Hong Journal: J Korean Med Sci Date: 2012-01-27 Impact factor: 2.153
Authors: Anju Gangadharan; Sung Eun Choi; Ahmed Hassan; Nehad M Ayoub; Gina Durante; Sakshi Balwani; Young Hee Kim; Andrew Pecora; Andre Goy; K Stephen Suh Journal: Oncotarget Date: 2017-04-04
Authors: Susanne Blauwhoff-Buskermolen; Jacqueline A E Langius; Annemieke C Heijboer; Annemarie Becker; Marian A E de van der Schueren; Henk M W Verheul Journal: Front Physiol Date: 2017-03-01 Impact factor: 4.566
Authors: Karin J C Sanders; Anita E M Kneppers; Coby van de Bool; Ramon C J Langen; Annemie M W J Schols Journal: J Cachexia Sarcopenia Muscle Date: 2015-09-07 Impact factor: 12.910